Business context and reporting period
The supplied filing is PerkinElmer, Inc.’s unaudited Form 10-Q, not a filing identified as Revvity, Inc. It covers the quarter and six months ended July 1, 2012; comparatives are the periods ended July 3, 2011. PerkinElmer reports Human Health and Environmental Health segments. The 2011 comparative figures were adjusted for accounting changes and presentation of product and service revenue.
Financial performance
| Metric | Q2 2012 | Q2 2011 | First half 2012 | First half 2011 |
|---|---|---|---|---|
| Revenue | $521.8M | $479.1M | $1,032.7M | $926.2M |
| Operating income | $49.8M | $39.4M | $86.2M | $80.9M |
| Continuing-operations net income | $33.6M | $29.1M | $55.6M | $56.4M |
| Net income | $33.6M | $29.8M | $56.2M | $54.7M |
| Diluted EPS | $0.29 | $0.26 | $0.49 | $0.49 |
| Gross margin | 45.8% | 43.7% | 45.6% | 44.2% |
- Q2 revenue rose 9%; Human Health revenue increased 18% to $258.4M, while Environmental Health rose 1% to $263.4M. First-half revenue increased 11%.
- Q2 operating margin increased to about 9.5% from 8.2%; higher volume, product mix and productivity supported margin expansion. First-half operating margin was about 8.3%, versus 8.7%.
- First-half interest and other expense rose to $24.2M from $10.0M, primarily reflecting higher debt and interest expense associated with the 2021 notes. This contributed to slightly lower continuing-operations net income despite higher operating income.
- Q2 comprehensive income was $3.6M, down from $46.3M, mainly because of a $30.3M foreign-currency translation loss recorded in other comprehensive income.
Cash flow, debt and liquidity
- First-half cash from continuing operating activities was $92.7M, versus $102.2M; total operating cash flow was $91.9M. Management cited timing of tax, restructuring, salary and benefit payments among working-capital factors.
- Continuing investing activities used $11.2M, including $11.4M of capital expenditures and no acquisition payments. Financing activities used $48.8M; dividends paid were $15.9M.
- Cash and cash equivalents were $171.4M at July 1, 2012, up from $142.3M at year-end. Current assets were $897.8M and current liabilities $587.7M.
- Long-term debt was $911.0M, compared with $944.9M at January 1. Debt comprised $264.0M drawn under a $700M revolving facility, $150M of 6% notes due 2015 and approximately $497M carrying value of 5% notes due 2021. The company reported $424.0M of additional revolver availability and compliance with applicable covenants.
Changes, outlook and notable items
- Caliper Life Sciences, acquired in November 2011, contributed to Human Health growth; acquisition-related revenue was an estimated 8% of Q2 growth and 9% of first-half growth. Unfavorable foreign exchange reduced reported revenue growth by about 4% in Q2 and 3% in the first half.
- Management described demand growth in diagnostics, medical imaging, laboratory services, and environmental and food-safety testing. It also cited weaker industrial-market demand and reduced pharmaceutical research spending, particularly in Europe.
- No specific company-wide revenue or earnings guidance was provided in the supplied filing. Management expected continued growth in relevant markets, while noting pressure on laboratory budgets and credit availability. It projected more than $10M in annual restructuring savings beginning in fiscal 2014; immediate savings were expected to approximately offset realignment spending.
- Restructuring and contract termination charges were $11.4M in the first half, versus $3.3M a year earlier. The Q2 plan targets 229 job reductions; management expected additional future charges and scheduled remaining severance payments through 2013.
- The company planned to repatriate about $350M of foreign earnings, with estimated taxes provided in 2011; $229.2M had been repatriated by July 1, 2012. It expected to complete the planned repatriation by fiscal 2013.
Risks, contingencies and unusual items
- Key risks include economic and customer-funding uncertainty, foreign exchange exposure, competition and product-development execution, acquisition integration, regulatory compliance, supply interruptions, and the company’s substantial debt and variable-rate exposure.
- PerkinElmer recorded a $5.5M environmental liability. It also disclosed the stayed Enzo patent and related claims litigation, which management did not expect to have a material adverse financial effect; outcomes remain uncertain.
- Gross tax-effected unrecognized tax benefits were $47.8M. The filing also noted open tax years in multiple jurisdictions and uncertain tax positions expected to be resolved within a year.
- Goodwill was $2.08B and net intangible assets $613.0M at July 1. The company reported no impairment in its annual 2012 testing and no first-half events requiring impairment testing of amortizing intangibles.
Important facts for investors to verify
- Confirm the intended issuer: this source is PerkinElmer, Inc., despite the request metadata naming Revvity, Inc.
- Assess whether Human Health growth excluding Caliper and currency effects supports ongoing organic growth, and whether Environmental Health’s slower growth persists.
- Track debt reduction, interest expense, revolver usage and covenant headroom, as well as cash availability across jurisdictions.
- Evaluate whether restructuring savings materialize on schedule and offset integration and research-and-development spending.
- Monitor foreign-exchange effects, repatriation-related cash taxes, tax uncertainties, and the resolution of litigation and environmental contingencies.